Intrexon Corp (OQ:XON)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 1750 Kraft Dr Ste 1400
BLACKSBURG VA 24060-6147
Tel: N/A
IR: See website
Key People
Randal J. Kirk
Executive Chairman of the Board
Helen Sabzevari
President, Chief Executive Officer
Thomas D. Reed
Founder, Chief Science Officer
Rick L. Sterling
Chief Financial Officer
Thomas Bostick
Chief Operating Officer
Jeffrey T. Perez
Senior Vice President ' Intellectual Property Affairs
Robert F. Walsh
Senior Vice President-Energy & Fine Chemicals
Donald P. Lehr
Chief Legal Officer
Business Overview
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company's domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company's synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. The Company's technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing (LEAP), and ActoBiotics platform.
Financial Overview
For the nine months ended 30 September 2019, Intrexon Corp revenues decreased 30% to $82.4M. Net loss decreased 9% to $153.1M. Revenues reflect Collaborationandlicensingagreements segment decrease of 12% to $15.3M. Lower net loss reflects FV/Uls Adjust on Derivatives for Hedging increase from $27.6M (expense) to $2.6M (income), Research and development - Balancing val decrease of 20% to $93.5M (expense).
Employees: 882 as of Dec 31, 2018
Reporting Currency: U.S. Dollars
Enterprise value: $978.73M as of Sep 30, 2019
Annual revenue (TTM): $125.55M as of Sep 30, 2019
EBITDA (TTM): -$393.84M as of Sep 30, 2019
Net annual income (TTM): -$493.57M as of Sep 30, 2019
Free cash flow (TTM): -$185.58M as of Sep 30, 2019
Net Debt Last Fiscal Year: $110.00M as of Sep 30, 2019
Shares outstanding: 162,511,940 as of Sep 30, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization